TVM Capital MENA, a healthcare focused fund which invests in emerging markets, will invest over $100 million in India in three-five years, top executive of the company announced on Wednesday.
The PE player, which has invested capital in international IVF chain Bourn Hall, which has operations in India, is looking to make more investments in the country.
“We are currently looking at the Indian healthcare market in greater detail and based on early indications we expect to invest no less than $100 million three-five years, but we are taking our steps with caution and at the right time,” said Helmut M Schühsler, chairman & chief executive officer, TVM Capital MENA.
TVM Capital MENA is part of TVM Capital Group which has around $1.2 billion assets under management across the world. While TVM Capital looks at both life sciences and healthcare space, TVM Capital MENA focuses on healthcare and looks at emerging markets like Africa, Middle East and India. Bourn Hall India is the first investment of the group in India.
“Bourn Hall Clinic in India has grown five times in the last one year and it will continue to deliver world class services leading to higher success rate. We will bring to India the cutting edge technologies and provide training to clinicians that will enable us to translate this to higher success among the childless couples and deliver to them what matters most: healthy babies,” said Gaurav Malhotra, managing director of Bourn Hall Clinic International, India.
The PE fund has committed up to $100 million in Bourn Hall India which has two clinics at present. The company has plans to set up 18 clinics in the country by end of fiscal year 2016. Bourn Hall India is looking at expansion through a hub and spoke model.
Indian healthcare space is seeing a lot of activity in single specialty companies for reasons like easy scalability, low capital expenditure and proved business models. The recent deals in the space include Modern Family Doctor securing investment from Saama Capital and Bamboo Finance, Sreyas Holistic Remedies securing $6.7 million from Evolvence India Life Sciences and Portea securing $8 million from Ventureast and Accel.
(Edited by Joby Puthuparampil Johnson)